Cardiovascular Diseases ; blood ; Erythrocyte Indices ; Erythrocytes ; Humans

No abstract available.
Cardiovascular Diseases/*blood/*epidemiology ; Humans ; Risk Factors ; Uric Acid/*blood

Circular RNA (circRNA) is a novel class of single-stranded RNAs with a closed loop structure. The majority of circRNAs are formed by a back-splicing process in pre-mRNA splicing. Their expression is dynamically regulated and shows spatiotemporal patterns among cell types, tissues and developmental stages. CircRNAs have important biological functions in many physiological processes, and their aberrant expression is implicated in many human diseases. Due to their high stability, circRNAs are becoming promising biomarkers in many human diseases, such as cardiovascular diseases, autoimmune diseases and human cancers. In this review, we focus on the translational potential of using human blood circRNAs as liquid biopsy biomarkers for human diseases. We highlight their abundant expression, essential biological functions and significant correlations to human diseases in various components of peripheral blood, including whole blood, blood cells and extracellular vesicles. In addition, we summarize the current knowledge of blood circRNA biomarkers for disease diagnosis or prognosis.
Autoimmune Diseases/blood* ; Biomarkers, Tumor/blood* ; Cardiovascular Diseases/blood* ; Humans ; Liquid Biopsy ; Neoplasms/blood* ; RNA, Circular/blood* ; RNA, Neoplasm/blood*

OBJECTIVES: The purpose of this study was to develop a program applying participatory action-oriented training (PAOT) methods for the management of cardiovascular disease risk factors and to assess its effectiveness in the workplace. METHODS: The cardiovascular disease risk factors of 817 workers in the workplace were assessed, and periodic health examination was conducted. Sixty-four workers (7.8%) were selected as a moderate-risk group and high risk group, and performed the participatory approach program for cardiovascular disease preventive management. RESULTS: The sixty-four workers who participated in the participatory approach program made a total of 246 action plans, 3.8 action plans per person and 115 action plans were achieved after three months, so that 46.7% of action plans have been achieved. In the intervention group that participated in the program, the rate of smoking decreased from 36.2% to 8.6% and systolic and diastolic blood pressure significantly decreased from 140.0+/-9.4 mmHg to 134.2+/-12.3 mmHg and from 92.6+/-7.1 mmHg to 80.0+/-9.8 mmHg respectfully. In addition, risk factor score also decreased by 0.3, whereas the control group who did not participate in the program also showed a significant reduction in the mean systolic and diastolic blood pressure. Regular exercise increased from 8.5% to 16.0%. CONCLUSIONS: To improve the effectiveness of the participatory approach program for the management of cardiovascular disease risk factors, the need to continues implementing programs and analysis of the long-term effects are required.
Blood Pressure ; Cardiovascular Diseases ; Humans ; Risk Factors ; Smoke ; Smoking

Most patients with hypertension and no definable cause are said to primary or essential hypertension, while other patients with hypertension and specific causes are siad to secondary hypertension. Approximately 5% fo patients with hypertension have specific causes. The patients of secondary hypertension should not be ignored for the reason: The elimination of cause for hypertension can normalize the blood pressure. Juxtaglomerular cell tumor is a rare condition of secondary hypertension, with only approximately 70 cases reported to date. The higher the level of blood pressure, the most likely that various cardiovascular diseases will develop prematurely through acceleration of atherosclerosis. But Acute myocardial infarction in young hypertensives has been reported rarely. We describe the rare case of a young patient with acute myocardial infarction associated with secondary hypertension by renal juxtaglomerular cell tumor.
Acceleration ; Atherosclerosis ; Blood Pressure ; Cardiovascular Diseases ; Humans ; Hypertension* ; Myocardial Infarction*

Optimizing treatment for hypertension has focused on reducing cardiovascular risk through reduction of mean blood pressure (BP) under the basic assumption that lower is better, as long as diastolic BP is sufficient to maintain coronary perfusion. However, antihypertensive therapy as currently practiced does not eliminate all hazards associated with BP elevation. Blood pressure variability (BPV) correlates closely with target-organ damage independent of mean BP and transient increases in BP are also triggers of vascular events. So far, there is no definitive outcome data relating specific reduction in BPV to decline cardiovascular events or death. Thus, the decision whether BPV should be considered a new therapeutic target is left to the clinical judgment of physicians and individualized for each patient. However, new evidence suggests that taking an antihypertensive medication at bedtime significantly affects BPV and lowers the risk of cardiovascular events and death. This strategy may provide a means of individualizing treatment of hypertension according to the circadian BPV of each patient and may be a new option to optimize BP control and reduce risk.
Blood Pressure ; Cardiovascular Diseases ; Circadian Rhythm ; Humans ; Hypertension ; Judgment ; Perfusion

Blood Circulation ; Cardiovascular Diseases ; therapy ; Humans ; Medicine, Chinese Traditional

Cardiovascular Diseases ; diagnosis ; genetics ; Humans ; MicroRNAs ; blood ; genetics

Many epidemiologic analyses and several clinical trials have shown that lowering blood pressure improved clinical outcomes. The benefits of lowering blood pressure were more prominent in cases of diabetes than in non-diabetic patients. Several randomized trials have demonstrated the benefit of lowering diastolic blood pressure to < 80 mm Hg in people with diabetes. However, the evidence for benefits associated with systolic blood pressure of < 130 mm Hg is limited. Recently, the Action to Control Cardiovascular Risk in Diabetes study reported that, in people with type 2 diabetes, targeting a systolic blood pressure (SBP) of less than 120 mm Hg, as compared with less than 140 mm Hg, did not reduce the rate of a composite outcome of fatal and nonfatal cardiovascular events. In actuality, a higher incidence of serious adverse events occurred in the group of SBP < 120 mm Hg. With lack of evidence demonstrating any benefit from lowering SBP to < 130 mm Hg, SBP < 130 mm Hg as a general target in the treatment of diabetes seems to be inappropriate. However, considering that several studies have reported a linear relationship between blood pressure and stroke, compared to the J-shaped relationship between blood pressure and cardiovascular disease, blood pressure goals need to be developed based upon the individualized characteristics of each patient.
Blood Pressure ; Cardiovascular Diseases ; Diabetes Mellitus ; Humans ; Hypertension ; Incidence ; Stroke

Since the new hypertension guideline published by the American Heart Association/American College Cardiology/American Society of Hypertension in 2017, the Korean Society of Hypertension and the European Society of Hypertension revised and announced new hypertension guidelines. Also the Korean Society of Hypertension published Korea hypertension fact sheet 2018, including prevalence, awareness, management status of hypertension, and their trends in Korea. Herein, I provide information on diagnosis and treatment of hypertension based on the new guidelines of the Korean Society of Hypertension.
Blood Pressure ; Cardiovascular Diseases ; Diagnosis ; Heart ; Hypertension ; Korea ; Prevalence